CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Amgen
National Institutes of Health Clinical Center (CC)
Lyell Immunopharma, Inc.
BeOne Medicines
Children's Hospital of Philadelphia
Fundación de investigación HM
Immatics US, Inc.
Beijing Biotech
Memorial Sloan Kettering Cancer Center
ModernaTX, Inc.
Hoffmann-La Roche
ModernaTX, Inc.
AstraZeneca
Regeneron Pharmaceuticals
Amgen
Beijing Biotech
AstraZeneca
Sumitomo Pharma America, Inc.
National Institutes of Health Clinical Center (CC)
Beijing Biotech
Beijing Biotech
Sellas Life Sciences Group
Dana-Farber Cancer Institute
A2 Biotherapeutics Inc.
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
BIOHENG THERAPEUTICS US LLC
Haihe Biopharma Co., Ltd.
University of Kansas Medical Center
DualityBio Inc.
Fondazione Italiana Linfomi - ETS
Australian & New Zealand Children's Haematology/Oncology Group
GlaxoSmithKline
Chinese PLA General Hospital
University of Alabama at Birmingham
Karyopharm Therapeutics Inc
Dana-Farber Cancer Institute
Bambino Gesù Hospital and Research Institute
MediLink Therapeutics (Suzhou) Co., Ltd.
Seqker Biosciences, Inc.
Novelwise Pharmaceutical Corporation
Regeneron Pharmaceuticals
Immatics Biotechnologies GmbH
UNC Lineberger Comprehensive Cancer Center
Regeneron Pharmaceuticals
BlueSphere Bio, Inc
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology